K. K. Muralidharan

Publications9
h-index4
Citations61
Highly Influential Citations3
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • I. Nestorov
  • 68 Publications, 2,049 Citations
  • L. Kappos
  • 687 Publications, 48,145 Citations
  • R. Fox
  • 337 Publications, 9,888 Citations
  • H. Hartung
  • 451 Publications, 15,774 Citations
  • Publications
  • Influence
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
Objective: To characterize the reversibility of natalizumab-mediated changes in pharmacokinetics/pharmacodynamics in patients with multiple sclerosis (MS) following therapy interruption. Methods:… Expand
  • 28
  • 1
Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis
Natalizumab (humanized immunoglobulin G4 antibody targeting alpha‐4 integrins) is a highly efficacious treatment for relapsing‐remitting multiple sclerosis (RRMS) that has been in clinical use since… Expand
  • 19
  • 1
A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis
The study's primary objective was to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of single subcutaneous (SC) or intramuscular (IM) 300‐mg doses of natalizumab with IV 300‐mg doses of… Expand
  • 10
  • 1
Exposure–disease response analysis of natalizumab in subjects with multiple sclerosis
Natalizumab, a human immunoglobulin monoclonal antibody that targets α4β1/α4β7 integrin, is an effective therapy approved for the treatment of multiple sclerosis (MS). The objective of this analysis… Expand
  • 4
Integrated Physiology/Obesity
2473-PUB Application of Translational Pharmacokinetic and Pharmacodynamic Modeling in the Development of GPR40 Partial Agonists DANIEL A. TATOSIAN, OSKAR ALSKAER, MARIA E. TRUJILLO, GEORGE EIERMANN,… Expand
Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing.
Natalizumab is approved for multiple sclerosis treatment at a dose of 300 mg every 4 weeks. Extended-interval dosing of natalizumab has been proposed as a strategy to mitigate the risk of progressive… Expand
Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Multiple Sclerosis – Peginterferon Beta‐1a, Daclizumab Beta, Natalizumab
COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'UN ACCIDENT VASCULAIRE CÉRÉBRAL ET D'AUTRES TROUBLES DU SNC
Reversibility of Natalizumab Effects on Peripheral Immune Cell Dynamics in Patients with Multiple Sclerosis